Dr. John Cush RheumNow
3 years 4 months ago
Predictors of DAPSA28 remission in #PsA starting 1st TNF-inhibitor (13 369 bio-naive pts from 13 Euro registries) showed 6 mo remission 25% and 12 retention 63%. Remission predictors: younger age, Dz duration, males (OR 1.85), CRP >10 (OR 1.52) https://t.co/cTefy6xeUB https://t.co/b2Ok6HJgE1
Dr. John Cush RheumNow
3 years 4 months ago
HRT for RA? Not Yet
Dr. Aurelie Najm discusses OP0268 presented at EULAR 2023 in Milan, Italy.
@AurelieRheumo
https://t.co/hoyZ2Ezn4G https://t.co/XWfE1RHwpi
I may be a snarky, opinionated curmudgeon, but I'm an optimist when and where it counts. And I think you should join me.
Dr. John Cush RheumNow
3 years 4 months ago
Abatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis receiving abatacept has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
https://t.co/XcOSLTgQVR https://t.co/ZfwAA0baRM
Dr. John Cush RheumNow
3 years 4 months ago
2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
These included 5 overarching principles & 10 recommendations on the role of imaging in making a diagnosis, monitoring, predicting, guiding therapy, and patient education in CiA.
https://t.co/5WoIm8OPZs https://t.co/xqNxDvuymJ
An analysis of a large rheumatoid arthritis cohort sheds light on biologic disease-modifying anti-rheumatic drugs (bDMARDs) clustering that may be used in management, as certain clusters of b/tsDMARD correlated with disease activity over time.
Dr. John Cush RheumNow
3 years 4 months ago
RheumNow’s newly launched Poster Hall features sponsor-generated clinical trial posters designed to educate and inform. Posters addressing vasculitis, AxSpa and nrAxSpa, and PMR now available.
https://t.co/0dV23VPDQH https://t.co/HfKhji40vU
Dr. John Cush RheumNow
3 years 4 months ago
Watch: Should you Assess Rheumatoid Factor Serially?
Dr. Jack Cush discusses abstract OP0272 at EULAR 2023 in Milan, Italy.
https://t.co/5e4SiPGDUM https://t.co/CzE597Auwg
Dr. John Cush RheumNow
3 years 4 months ago
Watch: De Novo Renal Nephritis Flares During Belimumab Trials
Drs. Yuz Yusof and Iaonnis Parodis discuss abstract POS1156 at EULAR 2023 in Milan, Italy.
https://t.co/XLzDF2VZ7Q https://t.co/iE16Ag3Rsu
Dr. John Cush RheumNow
3 years 4 months ago
How Often Do You Monitor MTX?
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow including new drug approval, a new SpA variant and new rules for methotrexate (MTX) monitoring and depression screening.
https://t.co/niPFjQTenh https://t.co/JyL8t6EexT
Dr. John Cush RheumNow
3 years 4 months ago
Pediatric Rheumatologist Loan assistance repayment program from HSRA. A loan assistance of up to $100,000 to eligible pediatric medical subspecialists in exchange for a 3-year, full-time service commitment at an approved facility in an underserved area https://t.co/6oFkEEKAY9
Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?
Dr. John Cush RheumNow
3 years 4 months ago
Chronic Pain Management tools
1 Medication
2 Physical Therapy
3 Cognitive-Behavioral Therapy
4 Mindfulness Meditation
5 Acupuncture
6 Massage
7 Heat/Cold
8 TENS
9 Yoga/Tai Chi
10 Support groups https://t.co/VBvYR8VK16 https://t.co/tbfPnL1VEH
While it is known that rheumatoid arthritis (RA) patients may be at risk for certain cancers, the question is which cancers and is this modified by therapy. This large, US claims analysis shows RA patients were nearly 2 times more likely (than those without RA) to develop lymphoma or lung cancer and that commonly used RA treatments were also unlikely to increase cancer risk.
